Hydrolases (3. ) (e.g., Urease, Lipase, Asparaginase, Muramidase, Etc.) Patents (Class 424/94.6)
  • Patent number: 10407671
    Abstract: The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: September 10, 2019
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Anthony Quinn, Alex J. Harvey
  • Patent number: 10344270
    Abstract: The present invention provides, among other things, improved methods for purifying I2S protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant I2S protein can be purified from unprocessed biological materials, such as, I2S-containing cell culture medium, using a process involving as few as four chromatography columns.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: July 9, 2019
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventor: Dave Nichols
  • Patent number: 10308920
    Abstract: The invention provides hydrolases, polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides, e.g., enzymes, having a hydrolase activity, e.g., an esterase, acylase, lipase, phospholipase (e.g., phospholipase A, B, C and D activity, patatin activity, lipid acyl hydrolase (LAH) activity) or protease activity, including thermostable and thermotolerant hydrolase activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The hydrolase activities of the polypeptides and peptides of the invention include esterase activity, lipase activity (hydrolysis of lipids), acidolysis reactions (to replace an esterified fatty acid with a free fatty acid), transesterification reactions (exchange of fatty acids between triglycerides), ester synthesis, ester interchange reactions, phospholipase activity and protease activity (hydrolysis of peptide bonds).
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: June 4, 2019
    Assignee: DSM IP ASSETS B.V.
    Inventors: Uwe T. Bornscheuer, David Weiner, Tim Hitchman, Jonathan Lyon, Sirirung Wongsakul
  • Patent number: 10293032
    Abstract: Viral infections of the eye, and particularly viral infections in the Herpesviridae and Adenoviridae families, can be treated by administration of a pharmaceutical made up of an enzymatically active ribonuclease and a vehicle. Advantageously, the enzymatically active ribonuclease is ranpirnase, the '805 variant, rAmphinase 2, and Amphinase 2, and the vehicle is an aqueous solution.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: May 21, 2019
    Assignee: TAMIR BIOTECHNOLOGY, INC.
    Inventors: Luis Squiquera, Jamie Sulley
  • Patent number: 10286046
    Abstract: The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: May 14, 2019
    Assignee: Seikagaku Corporation
    Inventors: Taiichi Sirogane, Takao Murayama, Masafumi Yaguchi
  • Patent number: 10265355
    Abstract: The present invention relates to a Myoviridae bacteriophage Esc-COP-1 that is isolated from the nature and can kill specifically Shigatoxin-producing type F18 E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12662BP), and a method for preventing and treating the infections of Shigatoxin-producing type F18 E. coli using the composition comprising said bacteriophage as an active ingredient.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: April 23, 2019
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Suk Hwang Park, Byung Kuk Kim
  • Patent number: 10196698
    Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for assessing prostate cancer. In a specific embodiment, present inventors have developed and applied a new technology and associated computation methods enabling simultaneous genome-scale analysis of genetic (copy number) and epigenetic (total methylation (TM) and allele-specific methylation (ASM) alternation, This method, called MBD-SNP, features affinity enrichment or methylated genomic DNA fragments using a methyl-binding domain polypeptide.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: February 5, 2019
    Assignee: The Johns Hopkins University
    Inventors: Srinivasan Yegnasubramanian, G. Steven Bova, Martin Aryee, William B. Isaacs, William G. Nelson
  • Patent number: 10188705
    Abstract: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: January 29, 2019
    Assignees: Icahn School of Medicine at Mount Sinai, Genzyme Corporation
    Inventors: Edward H. Schuchman, Robert J. Desnick, Gerald F. Cox, Laura P. Andrews, James M. Murray
  • Patent number: 10160960
    Abstract: Provided are mutant cocaine esterase polypeptides and PEGylated formulations thereof.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: December 25, 2018
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Donald Landry, Chang-Guo Zhan
  • Patent number: 10106854
    Abstract: The present application concerns methods and tools for diagnosing prostate cancer and furthermore concerns methods and tools for prognosing disease progression of prostate cancer. The method comprises determining methylation level of the genes C1orf114, HAPLN3, AOX1, GAS6, ST6GALNAC3 and ZNF660 and comparing the result with a control, thus obtaining a response which is used for diagnosing a prostate cancer and/or for prognosing aspects of an individual suffering from prostate cancer.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: October 23, 2018
    Assignees: Aarhus Universitet, Region Midtjylland
    Inventors: Torben Falck Ørntoft, Karina Dalsgaard Sørensen, Christa Haldrup
  • Patent number: 10093909
    Abstract: Polypeptides having phytase activity and polynucleotide sequences encoding the phytases are provided. The gene expresses the phytase at a level of at least 7 g/l to 40 g/L. The phytases have higher specific activity, retain activity at low pH, retain activity at high temperature, increased phosphorous equivalency, increased phosphorous bioavailability, and increased phosphorous hydrolysis. The phytases can be used in a variety of industries including food, feed, ethanol production, pharmaceuticals, and cleaning.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: October 9, 2018
    Assignee: BASF ENZYMES LLC
    Inventor: Arne I. Solbak, Jr.
  • Patent number: 10081800
    Abstract: Novel lactonases are provided.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: September 25, 2018
    Assignee: Fornia BioSolutions, Inc.
    Inventors: Goutami Banerjee, Jie Yang, Khin Oo, Xiyun Zhang, Eric Lin Hu, Tatsuya Fukushima
  • Patent number: 10058596
    Abstract: Methods and compositions for the enzymatic debridement of wounds are provided. Methods for preparing enzymatic debridement compositions are also provided. In one embodiment, an enzymatic debridement composition prepared by dissolving crude bromelain in a composition comprising a weak acid, and filtering and/or dialyzing the dissolved crude bromelain to obtain the enzymatic debridement composition is provided.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: August 28, 2018
    Assignee: KCI Licensing, Inc.
    Inventor: Douglas Philip Hanson
  • Patent number: 10016559
    Abstract: Embodiments relate to systems, methods and devices for delivering a drug or other therapy to a patient with an ambulatory infusion pump configured to provide a series of tolerance-building steps leading up to a plateau delivery rate. The plateau delivery rate is maintained until the prescribed amount of drug or therapy fluid is delivered to the patient. Embodiments of the invention include providing the patient or other user with a mechanism to decrease, or step down, the therapy delivery rate if a tolerance was not achieved at a lower rate, and providing notifications prior to a step up in a dosage delivery rate.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: July 10, 2018
    Assignee: Smiths Medical ASD, Inc.
    Inventors: David DeBelser, Clinton Robert Hetchler, David Pardee Sours, Michael Wade Kersch
  • Patent number: 9976187
    Abstract: Different combinations of methylation status based biomarkers can be used to test for prostate cancer with high sensitivity and high specificity.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: May 22, 2018
    Assignee: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Vladimir Bajic, Hicham Mansour, Roberto Incitti
  • Patent number: 9949925
    Abstract: Disclosed herein are bactericidal compositions that are effective against pathogenic biofilms, especially against biofilms formed by Pseudomonas aeruginosa. The disclosed compositions comprise escapin intermediate products which can reduce the biofilm viability and biofilm matrix of P. aeruginosa.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: April 24, 2018
    Assignee: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Charles D. Derby, Phang C. Tai, Eric S. Gilbert
  • Patent number: 9931437
    Abstract: The invention provides a scaffold of extracellular matrix polymers with recombinant chimeric peptides tethered thereto. The invention also provides recombinant chimeric peptides of antimicrobial peptides and extracellular matrix binding domains. The invention also provides methods for treating chronic wounds using the scaffold and/or recombinant chimeric peptides.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: April 3, 2018
    Assignee: WORCESTER POLYTECHNIC INSTITUTE
    Inventors: Marsha Rolle, Fioleda Prifti, Christopher Malcuit, Terri Anne Camesano, Tanja Dominko, Denis Kole
  • Patent number: 9914916
    Abstract: The present invention provides isolated dimeric Streptococcus-specific phage lysins having two Streptococcus-specific phage lysin monomers covalently linked to each other, and having killing activity against one or more Streptococcus bacteria. Also provided for are pharmaceutical compositions of dimeric lysins and their use in therapeutic treatment or alleviation of infections or bacterial colonizations. The dimeric lysins may also be used to decontaminate porous and non-porous surfaces or devices.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: March 13, 2018
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Vincent A. Fischetti, Gregory Resch
  • Patent number: 9896672
    Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: February 20, 2018
    Assignees: GREEN CROSS CORPORATION, MediGeneBio Corporation
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
  • Patent number: 9889203
    Abstract: Disclosed herein are methods of chemical conjugation comprising contacting a lysosomal enzyme with a first crosslinking agent to introduce aldehyde groups; contacting a lysosomal targeting peptide with a second crosslinking agent to introduce a hydrazide group at the N-terminal residue; contacting the lysosomal enzyme with aldehyde groups of step a. with the lysosomal targeting peptide with a hydrazide group at the N-terminal residue of step b; and forming a lysosomal enzyme-lysosomal targeting peptide conjugate.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 13, 2018
    Assignee: AMICUS THERAPEUTICS, INC.
    Inventor: Hung Do
  • Patent number: 9867875
    Abstract: Methods and compositions comprising recombinant Arginase I proteins which are capable of depleting the plasma arginine levels in a subject are disclosed. The methods and compositions can be used to modulate the activity of the immune system in a subject. Modulation of the immune system is useful in the treatment of immune disorders and in preventing rejection of a transplanted organ, tissue, or cell. The methods and compositions can also be used to treat a bone condition of a subject.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: January 16, 2018
    Assignee: BIO-CANCER TREATMENT INTERNATIONAL LIMITED
    Inventors: Gernot Schabbauer, Stephen Bluml, Emine Sahin-Heco, Paul Cheng, Li Chen
  • Patent number: 9844585
    Abstract: An embodiment of the invention is directed to a microfabricated, silicon-based, Convection Enhanced Delivery (CED) device. The device comprises a silicon shank portion, at least one individual parylene channel disposed along at least a part of an entire length of the shank, wherein the channel has one or more dimensioned fluid exit ports disposed at one or more respective locations of the channel and a fluid (drug) input opening. The fluid input opening may be configured or adapted to be connected to a fluid reservoir and/or a pump and/or a meter and/or a valve or other suitable control device(s) or apparatus that supplies and/or delivers fluid (e.g., a drug) to the microfabricated device. The device may have multiple channels disposed side by side or in different surfaces of the device. The device may be rigid, or flexible, in which case a flexible device can be attached to a bio-degradable support scaffold that provides sufficient structural rigidity for insertion of the device into the target tissue.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: December 19, 2017
    Assignees: YALE UNIVERSITY, CORNELL UNIVERSITY
    Inventors: William L. Olbricht, Keith B. Neeves, Conor Foley, Russell T. Matthews, W. Mark Saltzman, Andrew Sawyer
  • Patent number: 9839679
    Abstract: A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided. It has been found that administration of an enzyme that cleaves chondroitin sulfate proteoglycans to a patient disrupts extravasation of cells from the blood stream into tissue. The present invention provides methods of reducing penetration of cells associated with inflammation into tissue of a patient. Several methods are also provided for the regulation and suppression of inflammation comprising administering enzymes that digest chondroitin sulfates. Also provided are methods of treating and preventing inflammation associated with infection, injury and disease.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: December 12, 2017
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Elliott A. Gruskin, Jack L. Tseng, Anthony O. Caggiano
  • Patent number: 9839676
    Abstract: The invention provides a method for treating cancer in a subject or a method of inducing an anti-tumour effect including reducing tumour volume, inhibiting or slowing tumour growth, inhibiting tumour progression, altering the metabolic activity of a tumour, inducing quiescence of a tumour, inhibiting or reducing metastasis, inhibiting or reducing tumour invasiveness, reducing tumour weight, reducing tumour neovascularisation, improving time to disease progression (TDP) and/or improving survival, the method comprising administering to the subject an effective amount of angiogenin or an angiogenin agonist.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: December 12, 2017
    Assignees: Murray Goulburn Co-Operative Co., Limited, AGRICULTURE VICTORIA SERVICES PTY LTD
    Inventors: Peter Hobman, Andrew Brown
  • Patent number: 9827264
    Abstract: A method and system for identifying and treating various medical conditions caused by toxins, pathogens, hormonal imbalances and other factors involving intravenous therapy.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: November 28, 2017
    Inventor: Wyatt J. Palumbo
  • Patent number: 9814664
    Abstract: A composition for treating keratin surfaces to stimulate selective catabolysis and improve cellular viability comprising at least one autophagy activator and at least one DNA repair enzyme, and a method for improving selective catabolysis and cellular viability by treating with the composition.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: November 14, 2017
    Assignee: ELC Management LLC
    Inventors: Nadine A. Pernodet, Donald F. Collins, Dawn Layman, Daniel B. Yarosh
  • Patent number: 9816006
    Abstract: A coating process includes the successive steps of preparing the zone to be treated. At least one coat of a primer is applied to the prepared zone to obtain a thickness ranging from 100 to 450 micrometers. The zone to be treated is then reconditioned and a least one top coat is applied to obtain a thickness ranging from 100 to 450 micrometers.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: November 14, 2017
    Assignee: SARL SIMON
    Inventor: Dominique Simon
  • Patent number: 9765313
    Abstract: The present invention relates to the field of genetic engineering, in particular, the present invention relates to a method for producing a phytase variant with an improved thermal stability, and a phytase variant and the use thereof. The phytase variant contains at least one proline modification, compared to the phytase from Escherichia coli and other mutants thereof. The phytase variants with the modification have preferably improved properties, such as the thermal stability, optimal reaction temperature, pH property, specific activity, protease resistance and performance in animal feeds.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: September 19, 2017
    Assignee: Feed Research Institute, Chinese Academy of Agricultural Sciences
    Inventors: Bin Yao, Huoqing Huang, Huiying Luo, Chao Shao, Yingguo Bai, Yaru Wang, Peilong Yang, Pengjun Shi, Kun Meng, Heng Zhao, Rui Ma
  • Patent number: 9752197
    Abstract: The present invention relates to a method for detecting methylation of the bowel-cancer-specific methylation marker GPM6A (NM_201591, glycoprotein M6A) gene in order to diagnose bowel cancer, and more specifically relates to a method for providing information for diagnosing bowel cancer by detecting the methylation of a bowel-cancer-specific marker gene that is specifically methylated in bowel cancer cells. The method for detecting methylation and a diagnostic composition, kit and nucleic-acid chip according to the present invention can be used to advantage in diagnosing bowel cancer more accurately and quickly than by normal methods as they permit bowel cancer to be diagnosed at the initial genetic transformation step and so allow early diagnosis.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: September 5, 2017
    Assignee: GENOMICTREE, INC.
    Inventors: Sung Whan An, Tae Jeong Oh
  • Patent number: 9719074
    Abstract: The present invention provides, among other things, methods and compositions for production of recombinant I2S protein with improved potency and activity using cells co-express I2S and FGE protein. In some embodiments, cells according to the present invention are engineered to simultaneously over-express recombinant I2S and FGE proteins. Cells according to the invention are adaptable to various cell culture conditions. In some embodiments, cells of the present invention adaptable to a large-scale suspension serum-free culture.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: August 1, 2017
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Ferenc Boldog, Michael Heartlein
  • Patent number: 9714427
    Abstract: The present invention provides methods and compositions for inducing expression of Ube3a in a cell by contacting the cell with a topoisomerase inhibitor. Particular embodiments include a method of treating a genomic imprinting disorder, such as Angelman syndrome, in a subject by administering to the subject an effective amount of a topoisomerase inhibitor.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: July 25, 2017
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Benjamin David Philpot, Mark John Zylka, Bryan Leo Roth, John Arthur Allen, Hsien-Sung Huang
  • Patent number: 9687534
    Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: June 27, 2017
    Assignee: Curemark, LLC
    Inventor: Joan M. Fallon
  • Patent number: 9663775
    Abstract: The present invention relates to isolated polypeptides having lysozyme activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: November 23, 2012
    Date of Patent: May 30, 2017
    Assignee: Novozymes A/S
    Inventor: Kirk Matthew Schnorr
  • Patent number: 9655954
    Abstract: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: May 23, 2017
    Assignees: Icahn School of Medicine at Mount Sinai, Genzyme Corporation
    Inventors: Edward H. Schuchman, Robert J. Desnick, Gerald F. Cox, Laura P. Andrews, James M. Murray
  • Patent number: 9651558
    Abstract: The invention relates to bacterial cell surface display of post-translationally modified heterologous proteins. Provided is an isolated nucleic acid construct encoding a proteinaceous substance comprising, from the N-terminus to the C-terminus, at least (a) an N-terminal a lantibiotic leader sequence; (b) an amino acid sequence of interest to be post-translationally modified to a dehydroresidue- or thioether-bridge containing polypeptide; (c) a hydrophilic cell-wall spanning domain; (d) a sortase recognition motif; (e) a hydrophobic membrane spanning domain and (f) a C-terminal charged membrane anchoring domain. Also provided is a Gram-positive host cell expressing the construct, as well as a library of host cells.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: May 16, 2017
    Assignee: LanthioPep B.V.
    Inventor: Tjibbe Bosma
  • Patent number: 9631186
    Abstract: Disclosed herein are methods and compositions for generating a single-stranded break in a target sequence, which facilitates targeted integration of one or more exogenous sequences.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: April 25, 2017
    Assignee: Sangamo BioSciences, Inc.
    Inventor: Jianbin Wang
  • Patent number: 9597376
    Abstract: A lipoprotein lipase (LPL) protein for treating and/or preventing HTG and its associated diseases, including but not limited to acute pancreatitis (AP), and in particular, acute pancreatitis secondary to or exacerbated by hypertriglyceridemia, and hypertriglyceridemia and its associated diseases in general, including cardiovascular and metabolic diseases, endocrine disorders, and fat embolism syndrome.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: March 21, 2017
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Omar L. Francone, Lin Guey, Kevin Holmes, Bruce Tangarone, Matthew Traylor, Lenore von Krusenstiern, Tracy Dowie, Lieh Yoon Low, Bohong Zhang, Muthuraman Meiyappan, Angela Norton, Bettina Strack-Logue, Dianna Lundberg, Michael F. Concino
  • Patent number: 9597378
    Abstract: A blood coagulation factor VII derivative, a blood coagulation factor VIIa derivative, FacVII and FacVIIa conjugates are prepared by linking a polymer capable of extending the blood half-life to the derivative. FacVII and VIIa complexes each prepared by linking a carrier to the conjugate, genes encoding the FacVII and FacVIIa derivatives, expression vectors comprising the genes, transformants introduced with the expression vectors, a method for preparing the FacVII and FacVIIa derivatives using the transformants, a method for preparing the FacVIIa conjugate and complex, a FacVIIa complex prepared by the method, a pharmaceutical composition for the prevention or treatment of hemophilia comprising the derivative, conjugate, or complex as an active ingredient, and a pharmaceutical composition for blood coagulation comprising the derivative, conjugate, or complex as an active ingredient are described.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: March 21, 2017
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Dae Jin Kim, Byung Sun Lee, Sung Hwan Hong, Yong Ho Huh, Sung Youb Jung, Se Chang Kwon
  • Patent number: 9592279
    Abstract: An object of the present invention is to provide a substance which can be used as an active ingredient for improving neuropathic pain having a mechanism of action different from those of currently available agents and, therefore, provide an improving agent for neuropathic pain which rarely interacts with currently available agents and also does not have adverse reactions similar to those of currently available agents. An improving agent for neuropathic pain due to a hyperalgesic response of the present invention for resolution is characterized by comprising, as an active ingredient, a lyase (an elimination enzyme) which has an activity of degrading a chondroitin sulfate chain of a chondroitin sulfate proteoglycan, and is typified by chondroitinase ABC which selectively removes chondroitin sulfate and dermatan sulfate of a proteoglycan.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: March 14, 2017
    Assignees: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY, SEIKAGAKU CORPORATION
    Inventors: Yukihiro Matsuyama, Kenji Kadomatsu, Shiro Imagama, Akiomi Tanaka
  • Patent number: 9579365
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: February 28, 2017
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Tony Klink, John Kink, Laura Strong
  • Patent number: 9546360
    Abstract: Compositions and methods for the treatment of thrombotic thrombocytopenic purpura are disclosed.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: January 17, 2017
    Assignee: The Children's Hospital of Philadelphia
    Inventor: X. Long Zheng
  • Patent number: 9526765
    Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. In addition, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: December 27, 2016
    Assignees: The Kitasato Institute
    Inventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure
  • Patent number: 9526786
    Abstract: Provided are compositions comprising a cocaine esterase (CocE) and a compound that thermostabilizes the CocE. Also provided are methods of thermostabilizing a cocaine esterase. Additionally provided are methods of treating a mammal undergoing a cocaine-induced condition. Methods of determining whether a compound is a thermostabilizing agent for a protein are also provided. Uses of the above-described compositions for the treatment of a cocaine-induced condition is additionally provided. Additionally provided is an isolated nucleic acid encoding a CocE polypeptide having the substitutions L169K and G173Q, and the CocE polypeptide encoded by that nucleic acid, and pharmaceutical compositions thereof. Further provided is the use of that composition for the manufacture of a medicament for the treatment of a cocaine-induced condition and for the treatment of a cocaine-induced condition.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: December 27, 2016
    Assignees: The Trustee of Columbia University in the City of New York, The Regents of the University of Michigan
    Inventors: Donald W. Landry, James H. Woods, Roger K. Sunahara, Diwahar L. Narasimhan, Joanne MacDonald, Milan N. Stojanovic, John J. Tesmer, Remy L. Brim
  • Patent number: 9512413
    Abstract: The present invention relates to isolated polypeptides having organophosphorous hydrolase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: December 6, 2016
    Assignee: NOVOZYMES A/S
    Inventors: Bjarne Gram Hansen, Steffen Danielsen, Lars Kobberoee Skov, Leonardo De Maria, Julie Bille Rannes
  • Patent number: 9492511
    Abstract: The present invention provides, among other things, improved methods for purifying I2S protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant I2S protein can be purified from unprocessed biological materials, such as, I2S-containing cell culture medium, using a process involving as few as four chromatography columns.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: November 15, 2016
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventor: Dave Nichols
  • Patent number: 9474792
    Abstract: Methods of treating or ameliorating metabolic diseases using a PLA2G12A polypeptide or PLA2G12A mutant polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes mellitus, obesity, dyslipidemia elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 25, 2016
    Assignee: Amgen Inc.
    Inventors: Daniel C. H. Lin, Jinghong Wang, Yang Li
  • Patent number: 9441002
    Abstract: The thiol modified oligonucleotides have vast number of applications in the field of nucleic acid chemistry. The conjugates generated by mono thiol groups are unstable at higher temperature, in high salt concentration buffers and in presence other thiols. There is strong need to develop a novel thiol modifier probes that can generate multiple thiol groups. Described herein are efficient processes and compounds, dithiolane phosphoramidites derivative and dithiolane succinyl supports. The advantage of our cyclic disulfide thiol modifier is multifold a) each incorporation introduces two thiol groups; b) it can be introduced at any desired site of oligonucleotides; c) The symmetrical branching nature of the spacer in the linker arm of dithiolane allows for clean oligo synthesis, where cleavage of the linker arm and thereby of loss of oligo chain is prevented.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: September 13, 2016
    Assignee: ChemGenes Corporation
    Inventors: Suresh C. Srivastava, Santhosh Kumar Thatikonda, Sant K. Srivastav, Praveen K. Shukla, Alok Srivastava
  • Patent number: 9415014
    Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: August 16, 2016
    Assignee: Curemark, LLC
    Inventors: Joan M. Fallon, Matthew Heil
  • Patent number: 9382525
    Abstract: The present invention provides a site-specific pegylated arginase conjugate and method for producing thereof. The site-specific pegylated arginase is homogeneous in molecular weight and shows therapeutic effect for treating cancers and viral infections. The method for producing the arginase conjugate comprises genetically modifying the gene encoding an arginase so that the PEG moiety can be attached to the enzyme at a predetermined, specific intended sites. This is achieved by removing the PEG-attaching amino acid residue(s) at undesirable site(s) while keeping or adding cysteine(s) at the desirable site(s) of the enzyme. Two exemplary embodiments of the pegylated arginase conjugate are directed to human arginase I (HAI) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys45 of the enzyme and Bacillus caldovelox arginase (BCA) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys161 of the enzyme.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: July 5, 2016
    Assignee: The Hong Kong Polytechnic University
    Inventors: Yun Chung Leung, Wai-hung Lo
  • Patent number: RE47233
    Abstract: The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase fusion protein (AAD) for treating cancer or other arginine-dependent diseases. The AAD fission protein can be purified from both soluble and insoluble fractions of crude proteins, it binds to human serum albumin (HSA) and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD in the present invention are 8.4 and 9.2 U/mg (at physiological pH 7.4), respectively. The AAD used in the present invention can be used in the treatment of various cancers (e.g. pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer & brain cancer) and curing arginine-dependent diseases.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: February 12, 2019
    Assignee: Vision Global Holdings Ltd.
    Inventors: Bing Lou Wong, Norman Fung Man Wai, Sui Yi Kwok, Yun Chung Leung